Frequently Asked Questions on the Management of mCRC
Live Webinar

Frequently Asked Questions on the Management of mCRC

Colorectal cancer is a complex and molecularly heterogeneous disease characterized by a diverse genomic landscape. Practicing physicians are commonly challenged by questions related to use of molecular profiling, optimal treatment selection, and treatment sequencing. In this live webinar, experts will discuss frequently asked questions on the management of colorectal cancer and provide guidance on how to incorporate the latest advances in precision medicine into daily practice to optimize patient outcomes.

Faculty

Rui-Hua Xu, MD, PhD

Rui-Hua Xu, MD, PhD

Sun Yat-sen University Cancer Center

Guangzhou, China

Professor Xu Ruihua is currently a Professor in the Department of Medical Oncology at Sun Yat-Sen University (SYSU) Cancer Center, Guangzhou, China. He specializes in GI medical oncology, mainly engaged in the development of novel drugs and individualized treatment for GI cancer, and is a renowned oncology expert in China. Since 2014, he has also been the President of SYSU Cancer Center. Professor Xu was a visiting Associate Professor at the MD Anderson Cancer Center from 2002 to 2005. He is Vice President of the Chinese Society of Clinical Oncology (CSCO) and Chair of the Chinese Medical Oncology Group of Colorectal Cancer. He is a committee member of ASCO. Professor Xu’s primary research interests include the development of novel drugs for GI cancer, the design and conduct of phase I and II clinical trials to test these drugs, and translational research focused on developing prognostic and predictive markers in patients with GI cancer. He has established an international reputation in GI cancer and has served as a Steering Committee member in several global trials. He is now leading several clinical trials in China. He has published more than 160 peer-reviewed papers, including in renowned journals such as Journal of Clinical Oncology, Hepatology, Cancer Research, Leukemia, Clinic Cancer Research, and Cancer.

Tae-Won Kim, MD, PhD

Tae-Won Kim, MD, PhD

Asan Medical Center, University of Ulsan College of Medicine

Seoul, South Korea

Tae Won Kim, MD, PhD is the President of the Asan Cancer Institute and a Professor of Oncology at Asan Medical Center, University of Ulsan College of Medicine in Seoul, South Korea. Professor Kim is a board-certified medical oncologist with a sub-specialty in hematology-oncology. He received his undergraduate and medical degrees from Seoul National University, where he also completed his internship. He then completed his residency and fellowship at Asan Medical Center, where he also received his Master’s and Doctorate degrees. Thereafter, Professor Kim worked as a Postdoctoral Fellow at the Department of Hematology/Oncology at the University of Chicago. He has published more than 350 papers in international journals including Nature and Lancet Oncology, and his areas of interest include clinical and translational research of colorectal cancer, phase I clinical trials, and biomarker development.

Yanhong Deng, MD, PhD

Yanhong Deng, MD, PhD

Department of Medical Oncology

The Sixth Affiliated Hospital of
Sun Yat-sen University

Guangzhou, China

Professor Yanhong Deng is Head of the Cancer Center and Medical Oncology Unit at The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou. She also serves as Director of the Clinical Trial Center and Director of the Drug Clinical Trial Institution. Professor Deng’s main interests are clinical trials in gastrointestinal cancer, and translational research into molecular targeted therapy and immunotherapy.  Dr Deng is a member of the Expert Group of Standards for Diagnosis and Treatment of Colorectal Cancer in China (National Health Commission), Vice President of the Oncology Branch of Chinese Geriatrics Association, Vice Chairman of the Youth Committee of the Colorectal Cancer Professional Committee of the Chinese Anti-Cancer Association, Vice Chairman of the Youth Committee of Colorectal Tumor Branch of Chinese Medical Doctor Association, a member of ASCO and CSCO, and Chair of the Digestive Cancer Committee of Guangdong Women Doctors Association.

Takayuki Yoshino, MD, PhD

Takayuki Yoshino, MD, PhD

National Cancer Center Hospital East

Chiba, Japan

Dr Takayuki Yoshino, MD, PhD currently works at the National Cancer Center Hospital East (NCCE) in Kashiwa, Japan, where he is the Director for the Department of Gastroenterology and Gastrointestinal Oncology, the Head of the Clinical Research Coordinating Division, and the Head of the Translational Research Division. He has a particular interest in chemotherapy for gastrointestinal cancers, especially for colorectal cancer (CRC), where he focuses on various investigational new agents and translational research. Dr Yoshino has had over 200 peer‐reviewed scholar journal publications on metastatic CRC (mCRC), with several articles published in The Lancet, Journal of Clinical Oncology, New England Journal of Medicine, and Nature Medicine. In addition, he holds several professional appointments, serving on a Guidelines Steering Committee within the European Society of Medical Oncology (ESMO), a Chair of the Pan‐Asian adapted ESMO Guideline for mCRC, an Advisory Committee member of American Society (ASCO) Breakthrough, Editorial Board of ESMO/ASCO Global Curriculum, and the administrative board & a Vice Chair of the international affairs committee of both Japanese Society of Medical Oncology (JSMO) and Japan Society of Clinical Oncology (JSCO).

Timothy Price, MBBS, DHlthSc (Med), FRACP

Timothy Price, MBBS, DHlthSc (Med), FRACP

The Queen Elizabeth Hospital, Woodville and University of Adelaide

Adelaide, Australia

Professor Price’s research interest has been gastrointestinal cancer since 1998, when he was accepted for a Gastrointestinal Clinical Research Fellowship at the Royal Marsden Hospital in London. Subsequent roles have included Head of Cancer Research TQEH, Director of the Australasian Gastrointestinal Trials Group board since 2004, COSA board member since 2019, and current Medical Lead for Cancer Program Central Adelaide Health Network. He has authored or co-authored over 200 publications in peer-reviewed journals.

Claus-Henning Köhne, MD

Claus-Henning Köhne, MD

Klinikum Oldenburg

Oldenburg, Germany

Univ-Prof. Dr. med. Claus-Henning Köhne is Medical Director of the University Hospital of Oncology and Haematology at Klinikum Oldenburg (Germany). He studied medicine at the Medical School Hannover (Germany) and at the University of Glasgow (Scotland), specializing in internal medicine, hematology, and oncology. He has held senior positions at Humboldt-University/Charité of Berlin (Germany) and at the University Hospital Rostock (Germany). Prior to his current positions he was appointed Professor of Medical Oncology at the University Carl-Gustav-Carus of the Technical University Dresden (Germany). He is a member of several scientific organizations, including the European Society for Medical Oncology (ESMO), where he chaired the Oncology-Pro-Advisory-Group and organizes Preceptorship-Programmes on Colorectal Cancer; the American Society of Clinical Oncology (ASCO); the Gastrointestinal Tract Cancer Cooperative Group of the EORTC (GITCCG), as well as serving as a secretary for the EORTC; the Working Group for Internal Oncology (AIO Germany) of the German Cancer Society (DKG); and the German Society for Haematology and Oncology (DGHO); European Approval authority (EMA) in London; and the Institute for Applied Quality Promotion and Research in Health Care (AQUA). He is also the Head of the Wilsede School of Oncology, Hematology and Palliative Medicine. In addition, he chairs the advanced training committee of the Medical Association Lower Saxony in Oldenburg and is Chairman of the Tumour Center Society Weser-Ems. Prof. Köhne is appointed special guest Professor of the First Affiliated Hospital of Dalian Medical University (China) and also a visiting Professor of Dalian Medical University of the Second Affiliated Hospital (China), where he is also a member of the Sino-German Cancer Center Oldenburg (Dalian). In April 2017, he received the Dalian Friendship Award. Since August 2019, he is Visiting Professor of Fudan-University at Zhongshan-Hospital, Shanghai (China). Professor Köhne is also a reviewer of various journals, including the International Journal of Cancer, Oncology, Annals of Oncology, Critical Reviews in Oncology/Haematology, Onkologie, British Journal of Cancer, and Journal of Clinical Oncology, and he has served as board member of Annals of Oncology.

19:00        Welcome, introduction, and quiz
                  Rui-Hua Xu, MD, PhD

19:07        Key breakthroughs in the management of mCRC: Impact of the expanding biomarker landscape
                 Tae-Won Kim, MD, PhD

19:23        FREQUENTLY ASKED QUESTIONS

    • Q1. What conversion therapy should I use in RAS/BRAF wild-type CRC patients with initially unresectable liver metastases?
                  Yanhong Deng, MD, PhD

    • Q2. What sequence of therapy should I select for a patient with BRAFV600E-mutant mCRC?
                  Takayuki Yoshino, MD

    • Q3. When should I consider anti-EGFR rechallenge?
                 Timothy Price, MBBS, DHlthSc (Med), FRACP

    • Q4. How should I treat symptomatic MSI-H patients – immunotherapy or chemotherapy first?
                  Rui-Hua Xu, MD, PhD

    • Q5. What is the most appropriate treatment approach for patients with HER2-positive mCRC?
                 Claus-Henning Köhne, MD

20:48      Quiz questions revisited, faculty comments, and questions from the audience

20:58     Pearls for practice
               Rui-Hua Xu, MD, PhD

This meeting is designed specifically for oncologists, gastroenterologists, and other healthcare professionals involved in the management of colorectal cancer.

Upon completion of this educational activity, participants should be able to:

 

  • Identify current and emerging biomarkers and tools available for molecular genotyping to guide precision medicine in mCRC
  • Assess the role of liquid biopsy to identify patients who may benefit from anti-EGFR rechallenge
  • Select optimal treatment strategies, front-line and beyond progression, for distinct mCRC subtypes, including RAS wild-type, BRAF mutant, MSI-H, and HER2-positive

Provided by ACE Oncology.

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

The employees of ACE Oncology have disclosed no relevant financial relationships.

 

ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.